

2 7 AUG 2001 Days

Attorney Docket No. 210445



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ransberger et al.

Application No. 09/807,361

Filed: July 16, 2001

For: INFLUENCING HYPERACTIVE T

CELLS BY PROTEOLYTIC

**ENZYMES** 

#### **CERTIFICATE OF MAILING**

August 23, 2001

I hereby certify that the attached correspondence, including any documents or materials referred to thereon as enclosures or attachments, is being deposited with the United States Postal Service on the date shown above with sufficient postage as First-Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. ECH CENTER 1600/2900 Nikitiach

REQUEST FOR CORRECTED FILING RECEIPT

**Assistant Commissioner for Patents** Office of Initial Patent Examination **Customer Service Center** Washington, D.C. 20231

Dear Sir:

Applicants respectfully request that a corrected version of the Official Filing Receipt (copy enclosed) be issued in the above-identified patent application in order to correct the errors as follows:

The number of Drawings, which now reads "1," should be corrected to read --6--.

The number of Total Claims, which now reads "1," should be corrected to read --20--.

The title, which now reads "Utilization of proteolytic enzymes to influence hyperactive t cells," should be corrected to read --INFLUENCING HYPERACTIVE T CELLS BY PROTEOLYTIC ENZYMES--.

By:

Respectfully sulpmitted,

Carol/Larcher,/Registration No. 35,243 One of the Attorneys for Applicants LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: August 23, 2001



TTED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

GRP ART UNIT | FIL FEE REC'D | ATTY.DOCKET.NO | DRAWINGS IND CLAIMS TOT CLAIMS APPLICATION NUMBER FILING DATE 1645 990 210445 07/16/2001 09/807.361

**CONFIRMATION NO. 9189** 

23460 LEYDIG VOIT & MAYER, LTD TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6780



Date Mailed: 08/07/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Pat nt Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please JECH CENTER 1600/2900 submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Karl Ransberger, Seeshaupt, GERMANY; Gerhard Stauder, Geretsried, GERMANY;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP99/07634 10/12/1999

**Foreign Applications** 

GERMANY 198 47 114.9 10/13/1998

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

LEVOIG, VOIT & MAYER RECEIVED

AUG 1 3 2001

PATYTM Due Date

Title

Utilization of proteclytic enzymes to influence hyperactive t cells INFLUENCING HYPERACTIVE T CELLS BY PROTEOLYTIC FNZYMES Preliminary Class

Data entry by : NGUYEN, SON

Team : OIPE

Date: 08/07/2001



#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231